Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07249463 · ClinicalTrials.gov registry record · Phase 2
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
A Phase 2 study of Cryptosporidiosis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07249463 is a Phase 2 study of Cryptosporidiosis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07249463, a Phase 2 study of Cryptosporidiosis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study has the purpose to demonstrate prospect of benefit of EDI048 on clinical signs and symptoms of cryptosporidiosis to facilitate trial in target population, pediatric patients. This study aims to investigate the efficacy of a new chemical entity, EDI048, in a controlled human infection model of cryptosporidiosis induced by administration of ABO809 in healthy adults, who become symptomatic with disease thereby demonstrating a prospect of benefit for use of EDI048 in children afflicted with cryptosporidiosis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Cryptosporidium parvum oocysts (ABO809)
- DRUG EDI048
Study Locations (1)
Maryland
- Pharmaron Inc - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2027-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07249463
The ClinicalTrials.gov registry entry for NCT07249463 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cryptosporidiosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07249463 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07249463 about?
NCT07249463 is a clinical study titled "Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults". This study has the purpose to demonstrate prospect of benefit of EDI048 on clinical signs and symptoms of cryptosporidiosis to facilitate trial in target population, pediatric patients. This study aims to investigate the efficacy of a new chemical entity, EDI048, in a controlled human infection mod...
What is the current status of trial NCT07249463?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-08. Estimated completion is 2027-03-02.
What conditions does trial NCT07249463 study?
This clinical trial studies the following conditions: Cryptosporidiosis.
What interventions are being tested in trial NCT07249463?
The interventions under investigation include: Placebo (OTHER), Cryptosporidium parvum oocysts (ABO809) (BIOLOGICAL), EDI048 (DRUG).
Who is sponsoring clinical trial NCT07249463?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07249463 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cryptosporidiosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium
COMPLETED · Phase 2
-
Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study
COMPLETED · NA
-
A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.